新型旋转酶抑制剂Zoliflodacin的MIC质控范围确定
两项多实验室质控研究确立了Zoliflodacin对CLSI推荐ATCC菌株的MIC质控范围。八实验室按CLSI M23二级研究定义淋病奈瑟菌ATCC 49226琼脂稀释MIC质控范围为0.06-0.5 μg/ml;另一研究确定肉汤微量稀释法对金黄色葡萄球菌等5种菌的质控范围,均获CLSI批准。
要点
- 淋病奈瑟菌ATCC 49226琼脂稀释MIC质控范围为0.06-0.5 μg/ml。
- 金黄色葡萄球菌ATCC 29213肉汤微量稀释MIC质控范围为0.12-0.5 μg/ml。
- 质控范围将用于Zoliflodacin三期临床试验及后续监测和临床实验室。
核心结论
- Zoliflodacin对淋病奈瑟菌ATCC 49226的琼脂稀释MIC质控范围为0.06-0.5 μg/ml,已获CLSI批准。
- Zoliflodacin对金黄色葡萄球菌ATCC 29213等5种非淋病奈瑟菌菌株的肉汤微量稀释MIC质控范围已确定并获CLSI批准。
研究设计与样本
- 两项多实验室质控研究,其中一项为八实验室按CLSI M23定义的二级研究。
- 另一项研究采用肉汤微量稀释法确定多个ATCC菌株的MIC质控范围。
主要发现
- 淋病奈瑟菌ATCC 49226琼脂稀释MIC质控范围为0.06-0.5 μg/ml。
- 金黄色葡萄球菌ATCC 29213肉汤微量稀释MIC质控范围为0.12-0.5 μg/ml。
- 粪肠球菌ATCC 29212为0.25-2 μg/ml,大肠埃希菌ATCC 25922为1-4 μg/ml。
- 肺炎链球菌ATCC 49619为0.12-0.5 μg/ml,流感嗜血杆菌ATCC 49247为0.12-1 μg/ml。
关键数值与推荐
- 淋病奈瑟菌ATCC 49226琼脂稀释MIC质控范围:0.06-0.5 μg/ml。
- 金黄色葡萄球菌ATCC 29213肉汤微量稀释MIC质控范围:0.12-0.5 μg/ml。
- 粪肠球菌ATCC 29212肉汤微量稀释MIC质控范围:0.25-2 μg/ml。
- 大肠埃希菌ATCC 25922肉汤微量稀释MIC质控范围:1-4 μg/ml。
- 肺炎链球菌ATCC 49619为0.12-0.5 μg/ml,流感嗜血杆菌ATCC 49247为0.12-1 μg/ml。
临床怎么用
- 上述质控范围将用于Zoliflodacin体外药敏试验,包括三期人类临床试验和监测研究。
- 最终质控范围将推广至临床实验室用于Zoliflodacin药敏检测的质量控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This report describes the results of two different, multilaboratory quality control (QC) studies that were used to establish QC ranges for the novel gyrase inhibitor zoliflodacin against the ATCC strains recommended by the Clinical and Laboratory Standards Institute (CLSI). Following the completion of an eight-laboratory, CLSI document M23-defined tier 2 study, the agar dilution MIC QC range for zoliflodacin against the Neisseria gonorrhoeae QC strain ATCC 49226 was defined as 0.06 to 0.5 μg/ml and was approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing. This QC range will be used for in vitro susceptibility testing of zoliflodacin during phase 3 human clinical trials and surveillance studies, and eventually it will be implemented in clinical labs. In a separate study, broth microdilution MIC quality control ranges for zoliflodacin against additional QC strains were determined to be 0.12 to 0.5 μg/ml for Staphylococcus aureus ATCC 29213, 0.25 to 2 μg/ml for Enterococcus faecalis ATCC 29212, 1 to 4 μg/ml for Escherichia coli ATCC 25922, 0.12 to 0.5 μg/ml for Streptococcus pneumoniae ATCC 49619, and 0.12 to 1 μg/ml for Haemophilus influenzae ATCC 49247. These MIC QC ranges were also approved by CLSI for use in future in vitro susceptibility testing studies against organisms other than N. gonorrhoeae.
引用
- Miller AA, Traczewski MM, Huband MD, et al. Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin. J Clin Microbiol. 2019. PMID: 31315953. doi:10.1128/JCM.00567-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。